Basto-Abreu A, Reyes-García A, Stern D, Torres-Ibarra L, Rojas-Martínez R, Aguilar-Salinas CA, Romero-Martínez M, Campos-Nonato I, López-Ridaura R, Barrientos-Gutiérrez T

Language: Spanish
References: 19
Page: 530-538
PDF size: 292.46 Kb.

ABSTRACT

Objective. To update the type 2 diabetes (T2D) prevalence, and to estimate the cascades of screening and care for T2D in the Mexican adult population. Materials and methods. We used information from the National Health and Nutrition Survey 2023. We estimated the cascade of screening using the eligible population according to NOM- 015-SSA2-2010 and the T2D care cascade using diagnosed cases. Results. The prevalence of T2D was 18.4% (12.4% diagnosed and 6.0% undiagnosed); 83% of the adult population without a T2D diagnosis had risk factors that made them eligible for blood screening; from them, 27.7% were screened in the past year (goal 33.3%). From T2D cases, 72.8% visited the doctor at least once in the last year, 92.8% were under pharmacological treatment, 77.9% used treatment regularly and 25.8% had glycemic control. Patients that completed the three steps of care (follow-up, treatment and regular treatment) achieved slightly better glycemic control (34.4%). Conclusion. Mexico faces important challenges to guarantee screening, care and control of T2D. We propose some actions to improve the detection and control of T2D based on the evidence generated through screening and care cascades.

REFERENCES

1. Ong KL, Stafford LK, McLaughlin SA, Boyko EJ, Vollset SE, Smith AE, etal. Global, regional, and national burden of diabetes from 1990 to 2021,with projections of prevalence to 2050: a systematic analysis for the globalburden of disease study 2021. Lancet. 2023;402(10397):203-34. https://doi.org/10.1016/S0140-6736(23)01301-6

2. Instituto Nacional de Estadística y Geografía. Comunicado de prensa419/23. Estadísticas de defunciones registradas (EDR) 2022 (Preliminar).México: Inegi, 2023. Disponible en: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2023/EDR/EDR2022.pdf

3. Basto-Abreu A, López-Olmedo N, Rojas-Martínez R, Aguilar-Salinas CA,Moreno-Banda GL, Carnalla M, et al. Prevalencia de prediabetes y diabetesen México: Ensanut 2022. Salud Publica Mex. 2023;65(supl 1):s163-8.https://doi.org/10.21149/14832

4. Secretaría de Salud. Estrategia nacional para la prevención y el control delsobrepeso la obesidad y la diabetes. México: SS, 2017. Disponible en: https://www.gob.mx/salud/cenaprece/documentos/estrategia-nacional-para-laprevencion-y-el-control-del-sobrepeso-la-obesidad-y-la-diabetes-136837

5. American Diabetes Association. Screening for diabetes. Diabetes Care.2002;25(supl 1):21-4. https://doi.org/10.2337/diacare.25.2007.s21

6. Diario Oficial de la Federación. Norma Oficial Mexicana NOM-015-SSA2-2010, para la prevención, tratamiento y control de la diabetesmellitus. México: DOF, 2010 [citado mzo 13, 2024]. Disponible en: https://www.dof.gob.mx/normasOficiales/4215/salud/salud.htm

7. Secretaría de Salud. Cuestionario de factores de riesgo. México: SS,2015 [citado ene 12, 2024]. Disponible en: https://www.gob.mx/salud/documentos/cuestionario-de-factores-de-riesgo

8. Rojas-Martínez R, Escamilla-Núñez C, Castro-Porras L, Basto-Abreu A,Barrientos-Gutiérrez T, Romero-Martínez M, et al. Tamizaje, prevalencia,diagnóstico previo, tratamiento y control de hipertensión, hipercolesterolemiay diabetes en adultos mexicanos. Ensanut 2022. Salud Publica Mex.2023;65(6):685-96. https://doi.org/10.21149/15060

9. Centers for Disease Control and Prevention. Your diabetes care schedule.US: CDC, 2023 [citado mzo 13, 2024]. Disponible en: https://www.cdc.gov/diabetes/managing/care-schedule.html

10. Flores-Hernández S, Acosta-Ruiz O, Hernández-Serrato MI, Delgado-Rodríguez S, Reyes-Morales H. Calidad de la atención en diabetes tipo 2,avances y retos de 2012 a 2018-19 para el sistema de salud de México.Salud Publica Mex. 2020;62(6):618-26. https://doi.org/10.21149/11876

11. Romero-Martínez M, Cuevas-Nasu L, Gaona-Pineda EB, Shamah-LevyT. Nota técnica de la Encuesta Nacional de Salud y Nutrición Continua2023: resultados del trabajo de campo. Salud Publica Mex. 2024;66(3):304-6. https://doi.org/10.21149/15604

12. Basto-Abreu A, Reyes-García A, Stern D, Torres-Ibarra L, Rojas-Martínez M, Campos-Nonato I, et al. Apéndice al artículo: Análisisy recomendaciones para las cascadas de tamizaje y atención de ladiabetes tipo 2 en México. Figshare, 2024. https://doi.org/10.6084/m9.figshare.26360365.v2

13. ElSayed NA, Aleppo G, Aroda VR, Bannuru RR, Brown FM, BruemmerD, et al. 2. Classification and diagnosis of diabetes: standards of care in diabetes-2023. Diabetes Care. 2023;46(supl 1):19-40. https://doi.org/10.2337/dc23-S002

14. Secretaría de Salud. Protocolo clínico para el diagnóstico y tratamientode la diabetes. México: SS, 2015 [citado jul 17, 2024]. Disponible en:https://www.gob.mx/salud/documentos/protocolo-clinico-para-el-diagnostico-y-tratamiento-de-la-diabetes

15. American Diabetes Association Professional Practice Committee.2. Classification and diagnosis of diabetes: standards of medical carein diabetes-2022. Diabetes Care. 2022;45(supl 1):17-38. https://doi.org/10.2337/dc22-S002

16. American Diabetes Association Professional Practice Committee. 6.Glycemic goals and hypoglycemia: standards of care in diabetes-2024.Diabetes Care. 2024;47(supl 1):111-25. https://doi.org/10.2337/dc24-S006

17. Moreno-Loaeza L, Escamilla-Núñez MC, Sevilla-González MDR, García-De la Torre GS, Castro-Porras LV, Denova-Gutiérrez E, et al. Diagnosticperformance of questionnaires to identify individuals with impairedfasting glucose in Mexican adult population. Diabetes Res Clin Pract.2023;195:110186. https://doi.org/10.1016/j.diabres.2022.110186

18. Moody A, Cowley G, Ng-Fat L, Mindell JS. Social inequalities in prevalenceof diagnosed and undiagnosed diabetes and impaired glucose regulationin participants in the health surveys for England series. BMJ Open.2016;6(2):e010155. https://doi.org/10.1136/bmjopen-2015-010155

19. Kaul P, Chu LM, Dover DC, Yeung RO, Eurich DT, Butalia S. Disparitiesin adherence to diabetes screening guidelines among males andfemales in a universal care setting: a population-based study of 1,380,697adults. Lancet Reg Health Am. 2022;14:100320. https://doi.org/10.1016/j.lana.2022.100320